Fluimucil-antibiotic IT powder for injection 500 mg No. 3 buy in Moscow at a price of 794 rubles

Buy Fluimucil-antibiotic IT powder for injection 500 mg No. 3 in pharmacies

Brief description FLUIMUCIL ANTIBIOTIC is a mucolytic agent that thins sputum, increases its volume, and facilitates the separation of sputum.

Pharmacological action Thiamphenicol glycinate acetylcysteinate is a complex compound that combines the antibiotic thiamphenicol and the mucolytic acetylcysteine. After absorption of thiaminephenicol, glycinate acetylcysteinate is split into acetylcysteine and thiamphenicol. Thiamphenicol is a derivative of chloramphenicol, the mechanism of action is associated with inhibition of bacterial cell protein synthesis. Thiamphenicol has a wide spectrum of antibacterial action and is effective in vitro against bacteria that most often cause respiratory tract infections: gram-positive (Streptococcus pneumoniae, Corynebacterium diphtheriae, Staphylococcus spp., Streptococcus pyogenes, Listeria spp., Clostridium spp.) and gram-negative (Haemophilus influenzae, Neisseria spp., Salmonella spp., Escherichia coli, Shigella spp., Bordetella pertussis, Yersinia pestis, Brucella spp., Bacteroides spp.). Acetylcysteine, by breaking the disulfide bonds of mucoproteins, quickly and effectively dilutes sputum and pus, reduces their viscosity and promotes discharge. Acetylcysteine facilitates the penetration of the antibiotic thiamphenicol into lung tissue and inhibits the adhesion of bacteria to the epithelium of the respiratory tract.

Indications: diseases of the upper respiratory tract and ENT organs: exudative otitis media, sinusitis, laryngotracheitis; - diseases of the lower respiratory tract: acute and chronic bronchitis, prolonged pneumonia, lung abscess, emphysema, bronchiectasis, cystic fibrosis, bronchiolitis, whooping cough; — prevention and treatment of bronchopulmonary complications after thoracic surgery (bronchopneumonia, atelectasis); — prevention and treatment of obstructive and infectious complications of tracheostomy, preparation for bronchoscopy, bronchoaspiration; — with concomitant nonspecific forms of respiratory infections to improve drainage, including cavernous lesions, with mycobacterial infections. Method of administration and dosage Fluimucil® antibiotic IT is administered intramuscularly, used for inhalation, application, and cavity rinsing. Inhalation: adults - 250 mg 1-2 times a day; children - 125 mg 1-2 times a day. Endotracheal: through a bronchoscope, endotracheal tube, tracheostomy - 1-2 ml of solution (for adults, dissolve in 4 ml of water for injection - 500 mg of dry matter, for children - 250 mg). Locally: for administration into the paranasal sinuses, as well as for washing cavities after surgical interventions in the area of the nose and mastoid process, 1-2 ml of solution (for adults, dissolved in 4 ml of water for injection - 500 mg of dry matter, for children - 250 mg ). For diseases of the nasopharynx and ear, instill 2-4 drops into each nasal passage or external auditory canal. Intramuscularly: adults - 500 mg 2-3 times a day; children under 3 years old - 125 mg 2 times a day; 3-7 years - 250 mg 2 times a day; 7-12 years - 250 mg 3 times a day. For premature and newborn babies up to 2 weeks, the average dose is 25 mg/kg per day. If necessary, the dose can be increased by 2 times (in the first 2-3 days of treatment in particularly severe cases). Do not increase the dose in premature and newborn children, as well as in patients over 65 years of age. The course of treatment is no more than 10 days.

Side effects Allergic reactions. With intramuscular administration, a slight burning sensation at the injection site is possible, rarely - reticulocytopenia, anemia, leukopenia, neutropenia, thrombocytopenia. With inhalation administration - reflex cough, local irritation of the respiratory tract, stomatitis, rhinitis, nausea. Bronchospasm is possible, in which case bronchodilators are prescribed.

Contraindications - anemia; - leukopenia; - thrombocytopenia; - hypersensitivity to one of the components of the drug. With caution: with liver failure and chronic renal failure. In children of the first two years of life due to age-related characteristics of kidney function.

Overdose Symptoms: changes in bacterial flora, superinfections. It is possible that the side effects of the drug may increase (with the exception of allergic reactions). Maintenance therapy is recommended.

Special instructions During treatment, the peripheral blood picture should be monitored. If the number of leukocytes (less than 4 thousand/μl) and granulocytes (by more than 40%) decreases, the drug is discontinued. Fluimucil IT antibiotic solution should not come into contact with metal and rubber surfaces. Fluimucil® antibiotic IT does not affect the ability to drive vehicles and other mechanisms.

Interaction with other drugs The simultaneous administration of antitussives may increase sputum stagnation due to suppression of the cough reflex. It is not recommended to mix with other aerosol medications.

Storage conditions At temperatures from 15°C to 25°C. Keep out of the reach of children.

Shelf life: lyophilisate for the preparation of solution for injection and inhalation 500 mg (bottles) - 3 years; solvent: water for injection (ampoules) - 5 years; set - 3 years.

Experience in the use of combination drugs in the treatment of rhinitis and sinusitis in children

The incidence of sinusitis is still quite high. According to various authors, diseases of the nose and paranasal sinuses affect from 17 to 22% of the child population. One of the significant factors in the pathogenesis of acute and especially chronic inflammatory diseases of the nose and paranasal sinuses is a violation of the mechanism of mucociliary transport. This is most often associated with swelling of the mucous membrane, excessive formation and increased viscosity of nasal secretions, which entails a disorder of drainage, respiratory, secretory and olfactory functions. The most common treatment for sinusitis is oral or intramuscular antibiotics. Since the supply of antibiotics from the bloodstream to the site of inflammation is limited, the treatment of sinusitis must be comprehensive.

First of all, this should concern improving ventilation, as well as drainage of the paranasal sinuses and nasopharynx.

Until now, otolaryngologists do not always practice prescribing adequate mucoregulating drugs included in the treatment regimen for patients with sinusitis, which, by thinning the thick viscous secretion and improving mucociliary clearance, help remove secretions from the sinuses. Among the drugs that affect mucociliary activity, previously used drugs that stimulate the liquefaction of rhinobronchial secretions, or so-called mucolytics, which change the viscosity of the secretion, affecting its physicochemical properties. We are talking about enzymes (trypsin, chymotrypsin, etc.), which are not currently used due to side effects.

Drugs that reduce surface tension also have a mucolytic effect, i.e., they act on the gel phase of the discharge and dilute both sputum and nasopharyngeal secretions. This group includes fluimucil (N-acetylcysteine), the action of which is associated with the ability of the free sulfhydryl group of N-acetylcysteine to cleave the intermolecular disulfide bonds of mucus glycoprotein aggregates, exerting a strong liquefying effect and reducing viscosity in relation to any type of secretion: purulent, mucopurulent, mucous . The peculiarity of fluimucil is that in addition to the direct mucolytic effect, N-acetylcysteine has powerful antioxidant properties and is able to protect the respiratory system from the cytotoxic effects of inflammatory metabolites, environmental factors, and tobacco smoke.

In the group of mucolytics, combination drugs are of great interest, namely rhinofluimucil, which, in addition to N-acetylcysteine, which dilutes the secretions, includes a sympathomimetic - tuaminoheptane sulfate, which has a mild vasoconstrictor effect and does not cause excessive dryness of the mucous membrane. After the disulfide bridges break, mucus and phlegm lose their viscosity, begin to absorb water and are gently removed when blowing the nose, sneezing, or coughing. Indications for the use of rinofluimucil are:

prolonged purulent sinusitis with viscous thick secretion;
chronic rhinitis with the formation of crusts in the nasal cavity and nasopharynx;
vasomotor rhinitis with thick viscous discharge.

The effectiveness of the drug was assessed in a group of 55 patients aged 6 to 14 years; rinofluimucil was injected one dose into each half of the nose 3-4 times a day, the course was 6-7 days. The condition of the children was assessed by their subjective feelings before and after using the drug, as well as by objective criteria (reduction of hyperemia and congestion in the mucous membrane, improvement of nasal breathing, reduction of mucus, change in its rheological properties).

After 6-8 inhalations of rhinofluimucil, positive dynamics were noted.

The result of using the drug was assessed as follows: 70% of patients - excellent; 20% - good; 10% - satisfactory.

Drawing. Comparative results of treatment with the antibiotic fluimucil IT and traditional methods

There were no side effects from the use of the drug. The advantage of rhinofluimucil is that it acts on the surface of the mucous membrane and, by thinning the mucus, reduces its viscosity and promotes the productive physiological act of cleansing the nasal cavity.

The next drug that you should pay attention to is the fluimucil antibiotic IT, which combines two components in one dosage form: N-acetylcysteine and thiamphenicol glycinate (thiamphenicol is a drug from the chloramphenicol group). The spectrum of antimicrobial activity of the drug is presented in table. 1 (Clinical pharmacology of antibacterial drugs/Ed. Yu. B. Belousov, 1988).

The drug has a combined antibacterial and mucolytic effect and is recommended for the treatment of respiratory diseases caused by bacterial infection and accompanied by the formation of a thick viscous secretion. The antimicrobial activity of thiamphenicol is due to its interference with the synthesis of bacterial proteins. Recent studies have shown that the combination of thiamphenicol and N-acetylcysteine allows the drug to retain its unconjugated form and reach the site of inflammation in concentrations sufficient to create a bactericidal effect. The drug exhibits mucolytic activity against any type of secretion - mucous, mucopurulent, purulent. Fluimucil antibiotic IT facilitates the separation of sputum and nasal mucus. The drug is effective when administered into the paranasal sinuses.

We have data on treatment with the drug fluimucil-antibiotic IT in 37 children, of which 17 were diagnosed with acute sinusitis, 10 with exacerbation of chronic sinusitis and 10 with exacerbation of chronic purulent sinusitis. The control group of patients was treated using the traditional method without the use of fluimucil antibiotic. Comparative data is presented in the figure.

The drug was used for washing the paranasal sinuses after punctures or after surgery, including after endonasal opening of the ethmoidal labyrinth cells. Good results were obtained after 2-3 rinses: nasal breathing improved, swelling of the nasal mucosa decreased, the amount of secretion decreased, and its purulent nature disappeared. Indications and methods of use of the drug are presented in table. 2.

The effectiveness of the IT antibiotic fluimucil is determined not only by its antibacterial effect, but also by its ability to ensure rapid and complete removal of exudate, which in turn enhances the antibacterial effect.

Literature

Ammosova S.P., Chuchalin A.G. et al. The effectiveness of N-acetylcysteine therapy in the treatment of liquidators of the Chernobyl accident with chronic bronchitis.
Balyasinskaya G. L., Minasyan V. S., Kachkaeva E. D. The use of rinofluimucil in the treatment of rhinitis in children: Collection of works of the department. M., 2001. pp. 162-165.
Garashchenko T. I., Bogomilsky M. R., Radtsig E. Yu. Mucoactive drugs in the treatment of non-purulent diseases of the middle ear: Collection of works of the department. M., 2001. pp. 157-162.
Levin A. R., Zaitseva O. V., Vykhristyuk O. F., Kasyanov E. N. Results of the use of acetylcysteine in the complex treatment of children with bronchopulmonary diseases // Pediatrics. 1995. No. 5. P. 66-68.
Sinopalnikov A.I., Klyachkina I.L. The place of mucolytic drugs in the complex therapy of respiratory diseases // Russian Medical Bulletin. No. 4. pp. 9-10.
Samsygina G. A. et al. Experience in the use of acetylcysteine in the treatment of acute and chronic respiratory diseases in children // Pediatrics. 1995. No. 3. P. 76.
Rizzata J. Aerosol antibiotics for the treatment of respiratory infections. The focus is on thiamphenicol glycinate acetylcysteinate. Publishing house "Mattioli", 1985, Therapist, 2001. No. 9. P. 1-6.

Note!

Fluimucil antibiotic IT has the following pharmacological and therapeutic properties:

High bioavailability of the drug.
High antibacterial activity, which is achieved thanks to a special dosage form.
High mucolytic activity, ensuring the restoration of mucociliary clearance and the removal of pathological microorganisms.
By creating a high therapeutic concentration of both an antibiotic and N-acetylcysteine in the affected organs.